Arvi In Children Born With Congenital Heart Defects

dc.contributor.author	Ulugbekov Mirzo Ulugbek Oybek Ugli
dc.date.accessioned	2026-01-02T11:33:48Z
dc.date.issued	2024-04-19
dc.description.abstract	In the pre-epidemic period of ARI, 31 children aged 3–12 years with congenital heart defects (the main group) were assessed for the effectiveness of a preventive program with recombinant liposomal interferon alpha-2: 250,000 units once a day, 2 times a week for 1 month ( technique I). Due to insufficient effectiveness, we subsequently continued prophylaxis using method II: 250,000 units 2 times a day for 3 days, then 250,000 units once a day, 2 times a week for 1 month.
dc.format	application/pdf
dc.identifier.uri	https://geniusjournals.org/index.php/emrp/article/view/5885
dc.identifier.uri	https://asianeducationindex.com/handle/123456789/77809
dc.language.iso	eng
dc.publisher	Genius Journals
dc.relation	https://geniusjournals.org/index.php/emrp/article/view/5885/4919
dc.rights	https://creativecommons.org/licenses/by-nc/4.0
dc.source	Eurasian Medical Research Periodical; Vol. 31 (2024): EMRP; 11-13
dc.source	2795-7624
dc.subject	children
dc.subject	method
dc.subject	congenital heart defects
dc.title	Arvi In Children Born With Congenital Heart Defects
dc.type	info:eu-repo/semantics/article
dc.type	info:eu-repo/semantics/publishedVersion
dc.type	Peer-reviewed Article

item.page.files

pagination.showing.labelpagination.showing.detail

item.page.filesection.name: ugli_2024_arvi_in_children_born_with_congenital_he.pdf
item.page.filesection.size: 297.45 KB
item.page.filesection.format: Adobe Portable Document Format